Alltracel boosts Japanese firm's woundcare line:
This article was originally published in Clinica
Alltracel Pharmaceuticals has entered an agreement with Japanese consumer woundcare company Nichiban to develop and market Alltracel's m.doc "stop-bleeding" technology in Japan. The initial focus is to integrate the Dublin, Ireland-based company's SEAL.ON first aid treatment range, which incorporates m.doc's fast coagulating properties, into Nichiban's portfolio of woundcare brands. The Tokyo-based firm, which holds a 23% majority share of the Japanese consumer woundcare market, says it also plans to upgrade its own line-up of existing brands by introducing m.doc technology into the products.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.